The role of p53 in chemosensitivity and radiosensitivity - PubMed (original) (raw)
Review
. 2003 Oct 20;22(47):7486-95.
doi: 10.1038/sj.onc.1206949.
Affiliations
- PMID: 14576853
- DOI: 10.1038/sj.onc.1206949
Review
The role of p53 in chemosensitivity and radiosensitivity
Wafik S El-Deiry. Oncogene. 2003.
Abstract
The role of p53 as a central mediator of the DNA damage and other cellular stress responses is well established. The ultimate growth-suppressive function of p53 in part explains its ability to confer chemosensitivity and radiosensitivity upon tumor cells. Recent work in the field has added complexity to our understanding, in terms of identifying novel regulators of p53 stability and function, elucidation of the importance of the p53 family towards p53 function, a growing list of transcriptional targets as well as transcription-independent apoptotic effects and mechanisms, tissue specificity of the p53 response, a molecular understanding of p53-dependent therapeutic sensitization, and efforts towards molecular targeting of the p53 pathway. p53 remains an attractive target for drug development in cancer because its alteration provides a fundamental difference between normal and cancer cells. Strategies are emerging for the identification of mutant p53-specific therapies, therapies targeted at mutant p53-expressing tumors, as well as therapies that target various aspects of the p53 life cycle to enhance chemosensitization. The tools of molecular imaging are beginning to accelerate the pace of discovery and preclinical testing of p53 in animal models. The future holds promise for specific, individualized targeting of mutant or wild-type p53, or its transcriptional targets, in combination therapies with other cancer-specific drugs, to maximize tumor cell killing while protecting normal cells from toxic side effects.
Similar articles
- Targeting p53 for enhanced radio- and chemo-sensitivity.
Lu C, El-Deiry WS. Lu C, et al. Apoptosis. 2009 Apr;14(4):597-606. doi: 10.1007/s10495-009-0330-1. Apoptosis. 2009. PMID: 19259822 Review. - Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells.
Böhnke A, Westphal F, Schmidt A, El-Awady RA, Dahm-Daphi J. Böhnke A, et al. Int J Radiat Biol. 2004 Jan;80(1):53-63. doi: 10.1080/09553000310001642902. Int J Radiat Biol. 2004. PMID: 14761850 - The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy AR, Bristow RG. Cuddihy AR, et al. Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):237-57. doi: 10.1023/B:CANC.0000031764.81141.e4. Cancer Metastasis Rev. 2004. PMID: 15197326 Review. - Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.
Vernole P, Tedeschi B, Tentori L, Levati L, Argentin G, Cicchetti R, Forini O, Graziani G, D'Atri S. Vernole P, et al. Mutat Res. 2006 Feb 22;594(1-2):63-77. doi: 10.1016/j.mrfmmm.2005.07.011. Epub 2005 Sep 1. Mutat Res. 2006. PMID: 16139849 - Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
Bristow RG, Peacock J, Jang A, Kim J, Hill RP, Benchimol S. Bristow RG, et al. Oncogene. 2003 May 15;22(19):2960-6. doi: 10.1038/sj.onc.1206405. Oncogene. 2003. PMID: 12771947
Cited by
- The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells.
Sue SH, Tseng WC, Wu ZS, Huang SM, Chen JL, Wu ZF, Lai HC. Sue SH, et al. J Ovarian Res. 2024 Sep 14;17(1):187. doi: 10.1186/s13048-024-01509-x. J Ovarian Res. 2024. PMID: 39272193 Free PMC article. - ECRG2/SPINK7 Tumor Suppressor as Modulator of DNA Damage Response.
Patel H, Sheikh MS, Huang Y. Patel H, et al. Int J Mol Sci. 2024 May 28;25(11):5854. doi: 10.3390/ijms25115854. Int J Mol Sci. 2024. PMID: 38892042 Free PMC article. Review. - The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E, Sandoz J, Romero G, Zadra I, Urgel-Solas J, Borredat P, Kourtis S, Ortet L, Martínez CM, Weghorn D, Sdelci S, Janic A. Abad E, et al. J Exp Clin Cancer Res. 2024 Apr 29;43(1):127. doi: 10.1186/s13046-024-03045-4. J Exp Clin Cancer Res. 2024. PMID: 38685100 Free PMC article. - Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Raychaudhuri R, et al. JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634. JCO Precis Oncol. 2024. PMID: 38662984 - A Second Career for p53 as A Broad-Spectrum Antiviral?
Harford JB. Harford JB. Viruses. 2023 Dec 3;15(12):2377. doi: 10.3390/v15122377. Viruses. 2023. PMID: 38140618 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous